{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.38","upperLimit":"20.76","value":"12.6"},{"groupId":"OG001","lowerLimit":"5.45","upperLimit":"7.16","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"120"}],"units":"Participants"}],"description":"Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as \\>/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as \\>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m\\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.","id":"OG001","title":"Lapatinib + Capecitabine"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants on the basis of the treatment assigned at randomization. Only participants with an objective response were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)","title":"Duration of Objective Response (DOR) as Assessed by an IRC","type":"SECONDARY","unitOfMeasure":"Months"}